Comparative Studies on Microinjected High-mobility-group Chromosomal Proteins, HMG1 and HMG2

LILY WU, MARTIN RECHSTEINER, and LEROY KUEHL
Departments of Biochemistry and Biology, University of Utah, Salt Lake City, Utah 84112

ABSTRACT The nonhistone chromosomal proteins, HMG1 and HMG2, were iodinated and introduced into HeLa cells, bovine fibroblasts, or mouse 3T3 cells by erythrocyte-mediated microinjection. Autoradiographic analysis of injected cells fixed with glutaraldehyde consistently showed both molecules concentrated within nuclei. Fixation with methanol, on the other hand, resulted in some leakage of the microinjected proteins from the nuclei so that more autoradiographic grains appeared over the cytoplasm or outside the cells. Both injected and endogenous HMG1 and HMG2 partitioned unexpectedly upon fractionation of bovine fibroblasts, HeLa, or 3T3 cells, appearing in the cytoplasmic fractions. However, in calf thymus, HMG1 and HMG2 molecules appeared in the 0.35 M NaCl extract of isolated nuclei, as expected. These observations show that the binding of HMG1 and HMG2 to chromatin differs among cell types or that other tissue-specific components can influence their binding. Coinjection of [125I]HMG1 and [35S]HMG2 into HeLa cells revealed that the two molecules display virtually equivalent distributions upon cell fractionation, identical stability, identical intracellular distributions, and equal rates of equilibration between nuclei. In addition, HMG1 and HMG2 did not differ in their partitioning upon fractionation nor in their stability in growing vs. nongrowing 3T3 cells. Thus, we have not detected any significant differences in the intracellular behavior of HMG1 and HMG2 after microinjection into human, bovine, or murine cells.

Chromatin contains a group of nonhistone proteins characterized by relatively low molecular weights (<30,000) and high contents of lysine and acidic amino acids. These proteins, designated high-mobility-group (HMG) proteins, can be extracted from chromatin with 0.35 M NaCl or 0.75 M HClO4, and are soluble in 2% trichloroacetic acid (19, 27). The four major members of this class, HMG1, HMG2, HMG14, and HMG17, have been purified to apparent homogeneity and well characterized (17, 18, 19, 27). Partial amino acid sequences for HMG1 and HMG2 and complete primary structures for HMG14 and HMG17 have been reported (17, 18, 19, 27). The four major members of this class, HMG1, HMG2, HMG14, and HMG17, have been purified to apparent homogeneity and well characterized (17, 18, 19, 27). Partial amino acid sequences for HMG1 and HMG2 and complete primary structures for HMG14 and HMG17 have been reported (17, 18, 19, 27). HMG proteins display a number of similarities to histones, but unlike histones, their synthesis is not coupled to that of DNA (29). Their high concentration, ~10^6 molecules per nucleus, suggests that they play a role in chromatin structure. It has recently been shown that HMG14 and HMG17 bind and restore DNase I sensitivity to nucleosome core particles depleted of HMGs (58, 59). Thus, HMG14 and HMG17 appear to confer a special, nucleosome-sensitive structure on active genes. The role(s) of HMG1 and HMG2 are less clear.

HMG1 and HMG2 display remarkable structural similarities and presumably share a common ancestral gene. Their N-terminal sequences differ by only one amino acid in the first 21 residues (54). The C-terminal portion of HMG1 has a continuous run of 41, and HMG2 of 35, aspartic and glutamic acid residues (52, 55). About two-thirds of their tryptic peptides appear identical (53). Between pH 4 and pH 10, both HMG1 and HMG2 exist in a highly structured conformation with 40–50% α-helix (1, 8), and both proteins interact with double-stranded DNA in a similar manner (25, 26, 47). Both have been reported to bind to specific subfractions of histone H1 (48, 61), although this has been disputed (9). Like HMG14 and HMG17, HMG1 and HMG2, or the homologous trout protein, HMG14 and HMG17 have been reported to be concentrated in transcriptionally competent regions of the genome, as demonstrated by their release from chromatin by nuclease under conditions which preferentially digest transcriptionally active sequences (31, 33, 34, 39, 50). However, this is also disputed (16).

Despite their many similarities, HMG1 and HMG2 are distinct proteins with different sequences and different physical properties. Recently, Seyedin and Kistler (46) measured the levels of HMG1 and HMG2 in a number of rat organs and observed a striking correlation between the HMG2 levels and the proliferative activity of the tissues. HMG1 levels, on the
other hand, did not show marked organ variability. In an extension of this observation, it was shown that, in cryptorchid rat testis and in developing chick skeletal muscle, loss of proliferative activity was associated with a dramatic depletion of HMG2, and the authors suggested that HMG2 may play a role in cell replication.

We recently used erythrocyte-mediated microinjection to examine the fate of \[^{125}\text{I}]HMGI molecules introduced into HeLa cells and bovine fibroblasts (41). Injected HMG1 molecules rapidly concentrated within nuclei, and the chromatin-bound HMGI, which was shown to be in equilibrium with a small cytoplasmic pool of HMGI, displayed considerable stability. The observations of Seyedin and Kistler (46) suggest that HMGI and HMG2 differ in their metabolism. Our study was undertaken, in part, to compare the intracellular behavior of microinjected HMGI and HMG2, particularly their turnover rates. The dramatic changes in the level of HMG2 which accompany changes in proliferative activity suggested that HMG2 might have a shorter half-life than HMGI, since proteins whose intracellular concentrations are subject to wide fluctuations are frequently rapidly degraded (14, 15). We were also interested in comparing the binding of HMGI and HMG2 to chromatin. If HMG2, but not HMGI, is involved in cell replication, the two proteins might be expected to bind to chromatin at different sites and with different affinities.

Our studies were also undertaken to resolve an apparent discrepancy in the reported intracellular localization of HMGI. Bustin and Neihart stained several types of cultured cells with fluorescent antibodies directed against HMGI and observed considerable fluorescence over the cytoplasm (6). In fact, in some of their experiments, the cytoplasmic fluorescence was greater than that over the nucleus. Smith et al., using similar methods, failed to detect HMGI in the cytoplasm (49). Previous microinjection studies from our laboratory also revealed a predominantly nuclear localization for HMGI (41). Because antibodies to HMGI cross-react with HMG2 (3, 49), it seemed possible that the cytoplasmic fluorescence observed by Bustin and Neihart might be due to high concentration of HMG2 in the cytoplasm. Therefore, we thought it desirable to determine the intracellular distribution of injected HMG2.

Materials and Methods

Isolation and HMG Proteins

HMGI and HMG2 were prepared from calf thymus as described by Goodwin et al. (17). Upon electrophoresis on acid-urea gels or SDS gels, each purified protein was contained in one major band.

Iodination

HMGI and HMG2 were iodinated by an adaptation of the method of Miyachi et al. (36) as described earlier (41). All steps of the labeling procedure were performed in plastic ware because HMGI and HMG2 readily adsorb to glass. Usually ~75% of the \[^{131}\text{I}] or \[^{125}\text{I}\] was incorporated into the protein. Because the reaction mixtures contained \(1\times 10^6\) times as much HMG2 as lactoperoxidase, it was assumed that little of the label was associated with the latter. This assumption was supported by electrophoresis of iodinated HMGI molecules on acid-urea or SDS gels. Virtually all of the radioactivity coincided with the HMG bands.

Cell and Culture Techniques

The heteroploid human cell line D98/AH2 (CCL 183), the heteroploid bovine fibroblast line, EBT (CCL 44), and Swiss 3T3 cells (CCL 92) were obtained from the American Type Culture Collection (Rockville, Md.). Cells were cultured as previously described (45).

Loading, Microinjection, and Cell Fusions

The source of human erythrocytes and the general procedures for introducing proteins into them have been described in detail (40). For microinjection, the fusion mixture consisted of ~10 to 10\(^6\) cultured cells, 7.5 to 10\(^5\) loaded erythrocytes containing units of ultraviolet-inactivated Sendai virus, in a final volume of 0.5 ml of 0.15 M NaCl, 20 mM Tris, pH 7.4, containing 0.2-1 mM NaCl. The components were added in the order listed and kept on ice for 10 min before incubation with shaking at 37°C for 20 min. The cells were washed several times in F12 medium before plating.

Fixation, Sectioning, Autoradiography, and Fluorescence Microscopy

After plating onto glass cover slips, cells were washed twice with 0.15 M NaCl-20 mM Tris, pH 7.4, fixed for 1 h with 3% glutaraldehyde in 0.1 M sodium phosphate, pH 7.4, and washed thoroughly with distilled water. For comparative purposes, cells were fixed with methanol at ~20°C followed by acetone, as described by Bustin and Neihardt (6). Cells were embedded and sectioned as previously described (41). Autoradiographic procedures have been described in detail (42). After autoradiography, the slides were stained with Giemsa blood stain. Grain position and density were determined at \(\times 1,000\) magnification under oil using eyepiece reticles containing 10 \(\times\) 10 or 40 \(\times\) 40 grids. Cells containing fluorescent beads were examined with a Zeiss Photomicroscope II equipped with epi-fluorescence optics and filters matched for the detection of fluorescein.

Cell Fractionation

Nuclei were isolated from the washed cells by the double-detergent method of Penman (38) or, alternatively, by a procedure employing Triton X-100. In the former method, the cells were suspended in 10 mM NaCl-1.5 mM MgCl\(_2\)-10 mM Tris, pH 7.4 (RSB), at a concentration of 0.8-2.5 \(\times\) 10\(^6\) cells/ml and were ruptured by 10-12 strokes in a Dounce homogenizer with a tightly fitting pestle. The nuclei were sedimented and washed once with RSB and once with RSB containing 0.43% sodium deoxycholate and 0.86% Tween 40. Bovine fibroblast (BF) cells were more resistant to breakage than HeLa and were, therefore, homogenized after addition of detergent as well as before. In the Triton method, the cells were washed once with 25 mM KCl, 5 mM MgCl\(_2\), 50 mM Tris, pH 7.6, suspended in RSB containing 0.5% Triton X-100 at a concentration of 0.5-10 \(\times\) 10\(^6\) cells/ml, transferred to a Dounce homogemizer and subjected to 10-20 strokes (HeLa cells) or 50-100 strokes (3T3 and BF cells). Nuclei were sedimented and washed once with homogenization buffer. HeLa nuclei prepared by either method were clean as judged by phase-contrast microscopy, but BF and 3T3 nuclei were contaminated with adhering fragments of cytoplasm.

For autoradiographic studies, HeLa or BF nuclei, isolated by the Triton X-100 procedure, were fixed in 3% glutaraldehyde in 0.1 M sodium phosphate, pH 7.4, for 1 h at 4°C. The nuclei were then washed three times with absolute methanol and spread onto microscope slides. Although nuclei were often present in large aggregates, sufficient numbers of individual nuclei were present to allow autoradiographic localization of \[^{125}\text{I}]HMGI.

Electrophoresis

Two methods of electrophoresis on polyacrylamide gels were employed: the acid-urea system of Panyim and Chalkley (37) and the SDS system of Laemmli (32). Samples were applied in 6-mm-wide lanes to 1.5-mm-thick slabs of gel. For the Panyim-Chalkley system, a urea concentration of 6.25 M was employed and electrophoresis was for 4 h at 250 V. For the Laemmli system, the separating gel contained 15% acrylamide and 0.4% bisacrylamide. Electrophoresis was for 4 h at 50 V before the proteins entered the separating gel and 100 V thereafter. After electrophoresis, the gels were stained for 1 h in 0.25% amido black 10B-7% acetic acid-31.5% methanol and destained electrically in 7.5% acetic acid-22.5% methanol.

The concentration of HMG proteins in cell fractions was determined by scanning the electrophoretic pattern produced by the mixture with an Ortec Model 4310 densitometer and comparing the area under the HMG peaks with the areas generated by known amounts of the pure HMG molecules. For both HMGI and HMG2 the relationship between area and amount of protein was linear over the range investigated (0-15 \(\mu\)g of protein per lane).

Determination of Radioactivity

Radioactive samples were solubilized in NCS tissue solubilizer (Amerham/Searle Corp., Arlington Heights, Ill.) and counted on a Packard Model 3003 scintillation spectrometer (Packard Instruments Co., Inc., Downers Grove, Ill.) in toluene floor containing PPO (4 g/l) and POPP (0.1 g/l) or samples were
were counted in a Beckman Gamma 4000 spectrometer (Beckman Instruments, Indianapolis, Ind.). Fluorescent polystyrene beads were obtained from The Dow Chemical Company Mallinkrodt. Lactoperoxidase was obtained from Sigma Chemical Co. (St. Louis, Mo.). In those experiments which employed both \(^{125}\text{I}\) and \(^{131}\text{I}\) samples were intranuclear, these results show that microinjected HMG1 and HMG2 are loosely associated with chromatin and leak from nuclei during the isolation procedure. The extent of this leakage precluded detailed enzyme digestion studies.

HMG1 and HMG2 molecules are tightly associated with calf thymus chromatin at low-salt concentrations. The failure of most injected HMG1 and HMG2 molecules to remain within HeLa nuclei during fractionation suggested either that the injected proteins did not act like endogenous HMG1 and HMG2 or that HMG1 and HMG2 bind to HeLa chromatin differently than to calf thymus chromatin. To distinguish between these alternatives, HeLa cells and calf thymus were fractionated as described above, and the concentration of endogenous HMG1 in each fraction was determined. In these experiments, the detergent wash was omitted because the presence of detergents would have interfered with the isolation of the HMG-containing fraction from the various extracts. A comparison of Tables I and II demonstrates that endogenous HMG1 in HeLa cells behaved similarly to microinjected HMG1 upon cell fractionation. In both cases, nearly 80% of the recovered HMG1 was found in the RSB extracts.

The concentration of most injected HMG1 and HMG2 molecules to remain within HeLa nuclei during fractionation suggested that the injected proteins did not act like endogenous HMG1 and HMG2 or that the HMG1 and HMG2 bind to HeLa chromatin differently than to calf thymus chromatin. To distinguish between these alternatives, HeLa cells and calf thymus were fractionated as described above, and the concentration of endogenous HMG1 in each fraction was determined. In these experiments, the detergent wash was omitted because the presence of detergents would have interfered with the isolation of the HMG-containing fraction from the various extracts. A comparison of Tables I and II demonstrates that endogenous HMG1 in HeLa cells behaved similarly to microinjected HMG1 upon cell fractionation. In both cases, nearly 80% of the recovered HMG1 was found in the RSB extracts.

The endogenous HMG1 of calf thymus behaved differently from that of HeLa cells, because most of it appeared in the 0.35 M NaCl fraction as previously reported by Johns et al. (27). A trace amount of \(^{125}\text{I}\) labeled HMG1 added to the homogenates, fractionated similarly to the endogenous HMG1 of both HeLa cells and calf thymus. If it is assumed that HMG1 is quantitatively extracted from cells with 0.35 M NaCl, then it can be calculated from the data of Table II that HeLa cells contain \(2.3 \times 10^6\) and calf thymus \(2.9 \times 10^6\) molecules of HMG1 per cell. Comparison of the distribution of endogenous and injected HMG2 molecules during cell fractionation gave results virtually identical to those obtained for HMG1, except that there appear to be \(1.2 \times 10^6\) HMG2 molecules per HeLa cell.

The experiments presented above indicate that injected HMG1 and HMG2 fractionate like their endogenous counterparts in HeLa cells. The distribution of injected \(^{125}\text{I}\) HMG1 was also examined upon fractionation of injected BF cells, but the distribution of endogenous HMG1 in BF cells was not measured because of the expense in growing sufficient numbers of these cells. As with HeLa cells, a large portion (45%) of microinjected \(^{125}\text{I}\) HMG1 entered the low ionic strength buffer during homogenization of BF cells. However, after extraction with 0.35 M NaCl significantly more label (50%) remained associated with the residual nuclear fraction from BF cells.

Intracellular Distribution of Microinjected \(^{125}\text{I}\)-HMG2

When \(^{125}\text{I}\)-HMG2 molecules were injected into HeLa cells or bovine fibroblasts, they concentrated in the nuclei as demonstrated by autoradiography after glutaraldehyde fixation (Fig. 1A, see Fig. 2 for quantification). In parallel experiments, cells were fixed with cold methanol instead of glutaraldehyde. Although results obtained with methanol fixed cells were quite variable, it always appeared as though labeled molecules were being lost from the nuclei during fixation. In some experiments, the injected \(^{125}\text{I}\)-HMG2 appeared to have leaked from the cells and adsorbed to the glass substratum as shown by two- to threefold higher backgrounds and a reduction in the number of injected cells when compared with parallel cover slips fixed with glutaraldehyde (Fig. 1B). In other experiments, the leakage was not as extensive and was manifested primarily by lowered nuclear/cytoplasmic grain density ratios. For the data shown in Fig. 2, cover slips fixed and coded by one investigator were then evaluated by a second. The mean nuclear/cytoplasmic grain density ratio, determined after background subtraction, was 7.9 for 101 methanol-fixed cells and 16.4 for 108 cells that had been fixed in glutaraldehyde. This difference is significant at \(P < 0.001\) by the Wilcoxon rank sum test. Similar results were obtained for injected \(^{125}\text{I}\)-HMG1, so it would appear that methanol is not an entirely suitable fixative for the localization of HMG1 and HMG2 molecules within cells.

Microinjected \(^{125}\text{I}\)-HMG1 was previously shown to be localized within nuclei and not simply adsorbed to the nuclear envelope by autoradiographic analysis on thin sections of injected HeLa cells (41). Using the same procedure we showed that injected \(^{125}\text{I}\)-HMG1 molecules remained associated with metaphase chromosomes. In this study we have obtained the same results for injected \(^{125}\text{I}\)-HMG2. For BF cells fixed 48 h after injection, the mean density over 50 nuclei in sectioned cells was 5.7-fold greater than the corresponding cytoplasmic grain density. Similarly, qualitative analysis of autoradiograms of thin sections of injected BF cells fixed during metaphase revealed that \(^{125}\text{I}\)-HMG2 was concentrated in the spindle region presumably on metaphase chromosomes. Thus, the intracellular distribution of injected \(^{125}\text{I}\)-HMG2 is equivalent to that previously measured for \(^{125}\text{I}\)-HMG1.

Distribution of Microinjected HMG1 and HMG2 during Cell Fractionation

A major goal of this study was to compare the interaction of HMG1 and HMG2 with chromatin. If the two proteins serve different roles, as proposed by Seyadin and Kistler (46), their chromatin binding sites or binding affinities might vary. One way to detect any differences in binding would be to measure release of the two proteins from chromatin by enzymes or as a function of salt concentration. For this reason, HeLa cells were injected with a mixture of \(^{125}\text{I}\)-HMG1 and \(^{131}\text{I}\)-HMG2 and subsequently fractionated. As shown in Table I, the two molecules exhibited virtually identical distributions during fractionation. A large portion of each protein appeared in the cytoplasmic fraction. Because autoradiographic analysis indicated that >80% of injected HMG1 and HMG2 molecules were intranuclear, these results show that microinjected HMG1 and HMG2 are loosely associated with chromatin and leak from nuclei during the isolation procedure. The extent of this leakage precluded detailed enzyme digestion studies.

HMG1 and HMG2 molecules are tightly associated with calf thymus chromatin at low-salt concentrations. The failure of most injected HMG1 and HMG2 molecules to remain within HeLa nuclei during fractionation suggested either that the injected proteins did not act like endogenous HMG1 and HMG2 or that HMG1 and HMG2 bind to HeLa chromatin differently than to calf thymus chromatin. To distinguish between these alternatives, HeLa cells and calf thymus were fractionated as described above, and the concentration of endogenous HMG1 in each fraction was determined. In these experiments, the detergent wash was omitted because the presence of detergents would have interfered with the isolation of the HMG-containing fraction from the various extracts. A comparison of Tables I and II demonstrates that endogenous HMG1 in HeLa cells behaved similarly to microinjected HMG1 upon cell fractionation. In both cases, nearly 80% of the recovered HMG1 was found in the RSB extracts.

The concentration of most injected HMG1 and HMG2 molecules to remain within HeLa nuclei during fractionation suggested that the injected proteins did not act like endogenous HMG1 and HMG2 or that the HMG1 and HMG2 bind to HeLa chromatin differently than to calf thymus chromatin. To distinguish between these alternatives, HeLa cells and calf thymus were fractionated as described above, and the concentration of endogenous HMG1 in each fraction was determined. In these experiments, the detergent wash was omitted because the presence of detergents would have interfered with the isolation of the HMG-containing fraction from the various extracts. A comparison of Tables I and II demonstrates that endogenous HMG1 in HeLa cells behaved similarly to microinjected HMG1 upon cell fractionation. In both cases, nearly 80% of the recovered HMG1 was found in the RSB extracts.

The endogenous HMG1 of calf thymus behaved differently from that of HeLa cells, because most of it appeared in the 0.35 M NaCl fraction as previously reported by Johns et al. (27). A trace amount of \(^{125}\text{I}\)-labeled HMG1 added to the homogenates, fractionated similarly to the endogenous HMG1 of both HeLa cells and calf thymus. If it is assumed that HMG1 is quantitatively extracted from cells with 0.35 M NaCl, then it can be calculated from the data of Table II that HeLa cells contain \(2.3 \times 10^6\) and calf thymus \(2.9 \times 10^6\) molecules of HMG1 per cell. Comparison of the distribution of endogenous and injected HMG2 molecules during cell fractionation gave results virtually identical to those obtained for HMG1, except that there appear to be \(1.2 \times 10^6\) HMG2 molecules per HeLa cell.

The experiments presented above indicate that injected HMG1 and HMG2 fractionate like their endogenous counterparts in HeLa cells. The distribution of injected \(^{125}\text{I}\) HMG1 was also examined upon fractionation of injected BF cells, but the distribution of endogenous HMG1 in BF cells was not measured because of the expense in growing sufficient numbers of these cells. As with HeLa cells, a large portion (45%) of microinjected \(^{125}\text{I}\) HMG1 entered the low ionic strength buffer during homogenization of BF cells. However, after extraction with 0.35 M NaCl significantly more label (50%) remained associated with the residual nuclear fraction from BF cells.

Autoradiography of BF nuclei extracted with 0.35 M NaCl...
Figure 1 Autoradiograms of $[^{125}]$HMG2-injected HeLa cells. HeLa cells were fused with $[^{125}]$HMG2 loaded human erythrocytes, plated onto glass cover slips and fixed 16 h later with either 3% glutaraldehyde (A) or methanol-acetone (B). Autoradiographic exposure was 7 d.
showed that the residual $^{125}\text{I}$ was not present within the nuclei. Rather, the label was associated with material adhering to the nuclei. Nuclease digestion studies provided further evidence that the residual label in the nuclear fraction was not associated with chromatin. HeLa and BF cells were grown in medium containing 1 $\mu\text{Ci/ml }^32\text{P}$ for 48 h and then injected with $^{[125]}\text{HMG1}$. 24 h later, nuclei were isolated from each cell type and incubated in a mixture containing 400 U/ml DNAse I and 2,700 U/ml micrococcal nuclease for 20 min at $37^\circ\text{C}$ as described by Weintraub and Groudine (57). Whereas $^{32}\text{P}$ loss from the nuclei indicated that >90% of the DNA was digested, <15% of the $^{125}\text{I}$ in the nuclear fraction was solubilized. Attempts to solubilize the residual label with 5 M urea–2 M NaCl were also unsuccessful.

**Stability of Microinjected HMG1 and HMG2**

To determine whether $^{[125]}\text{HMG1}$ and $^{[131]}\text{HMG2}$ were degraded or altered after injection, extracts prepared from injected HeLa or BF cells between 7 and 43 h after injection were analyzed by electrophoresis and fluorography, as previously described (41). In eight different experiments between 84 and 100% of the radioactivity which was extracted into RSB during nuclear isolation migrated as HMG1 or HMG2. Thus, the radioactivity which can be reextracted from HeLa or BF cells injected with $^{[125]}\text{HMG1}$ or $^{[131]}\text{HMG2}$ is present as undegraded HMG molecules.

Although intracellular $^{125}\text{I}$ was quantitatively associated with the injected HMG molecules, this does not indicate that injected HMG molecules are stable. The degradation of any individual protein molecule is rapid, and iodotyrosine is quickly lost to the medium (62). Previously measured half-lives for microinjected $^{[125]}\text{HMG1}$ ranged from 60 to 120 h in HeLa and BF cells (41). Similar extractions of HeLa or BF cells at various times after injection of $^{[125]}\text{HMG2}$ indicated apparent half-lives of 55–120 h in HeLa and BF cells. The relative stabilities of HMG1 and HMG2 were directly compared by coinjection of $^{[125]}\text{HMG1}$ and $^{[131]}\text{HMG2}$ into HeLa cells. According to the data in Fig. 3, the half-lives of HMG1 and HMG2 are identical. Identical degradation rates for $^{[125]}\text{HMG1}$ and $^{[125]}\text{HMG2}$ were also observed in a second experiment with HeLa cells. Although we cannot exclude the possibility that the turnover rates of the microinjected HMG molecules differ from their endogenous counterparts, it should be noted that the half-lives determined in the above experiments are similar to those which have been reported for total HeLa cell proteins (12, 23). Evidence suggesting that the microinjected and endogenous HMGs are equivalent, will be considered in the discussion section.

**Equilibrium of Microinjected $^{[125]}\text{I}$HMG2 Molecules between Cytoplasm and Nucleus**

We previously showed that chromatin-bound HMG1 is in equilibrium with a cytoplasmic HMG1 pool (41). To determine whether this is also true of HMG2, HeLa cells microinjected

![Figure 2](image-url)
Nongrowing 3T3 Cells

40

80

TIME AFTER INJECTION (h)

FIGURE 3

Stabilities of [125I]HMG1 and [131I]HMG2 after coinjection into HeLa cells. Calf thymus HMG1 and HMG2 labeled with 125I and 131I, respectively, were injected into HeLa cells, and the cells were dispersed into culture flasks. Cells from duplicate flasks were removed at the times indicated, and the amounts of 131I and 125I in the cells were determined.

with [125I]HMG2 were fused with unlabeled cells which had been allowed to phagocytize fluorescent polystyrene latex beads. Binucleate cells produced by fusion of an injected and uninjected cell were identified by the presence of both radioactivity and fluorescent beads, and grain densities over the two nuclei in a number of such cells were determined at various times following cell fusion. The results of this experiment, which are presented in Fig. 4, demonstrate that [125I]HMG2 molecules fully equilibrated between the two nuclei by 12 h after the formation of binucleate cells. These results are indistinguishable from those previously obtained with [125I]HMG1 (41).

Stability of HMG1 and HMG2 in Growing and Nongrowing 3T3 Cells

Although expected on the basis of protein structure, the high degree of similarity between HMG1 and HMG2 in the studies just presented was surprising in view of the results of Seyedin and Kistler (46). Their observation that HMG2 rapidly disappeared in nongrowing tissues suggested that HMG1 and HMG2 would differ in the properties we have examined. However, because HeLa cells are continuously dividing, any difference between HMG1 and HMG2 strictly coupled to cell division might not be manifested. Accordingly, we re-examined the stability and partitioning of HMG1 and HMG2 in mouse 3T3 cells, since division of these cells can be controlled by serum concentration and cell density.

3T3 cells were injected with a mixture of [125I]HMG1 and [131I]HMG2 and then plated into regular F12 medium. After 20 h, the cells were collected by trypsinization, and some of the cells were plated into 100-mm petri dishes at high density in F12 medium containing 10% FCS; and still others were fractionated to determine the partitioning of [125I]HMG1 and [131I]HMG2 in 3T3 cells. The stabilities of HMG1 and HMG2 in growing and nongrowing 3T3 cells were determined by dissolving the cells in 1 ml of 100 mM NaOH at various times after plating. The amounts of [125I]HMG1 and [131I]HMG2 in each sample were determined by gamma spectroscopy. From these data, which are presented in Table III, along with further experimental details, it can be seen that there was no difference in the stabilities of HMG1 and HMG2 in 3T3 cells grown in high serum as compared to those grown in low serum. Yet, the proportion of cells synthesizing DNA differed 20-fold between high density and low density 3T3 cells by 5 d after plating, so we conclude that for 3T3 cells the degradation rates of HMG1 and HMG2 are unaffected by growth rate. The distribution of HMG1 and HMG2 during cell fractionation also did not vary with growth rate. Table IV presents the subcellular distribution of HMG1 and HMG2 before growth in high or low serum and 120 h later. It is clear that for 3T3 cells, at least, growth rate does not affect the distribution of HMG1 and HMG2 upon fractionation.

DISCUSSION

We have used microinjection to study the behavior of HMG molecules within living cells. The validity of our approach depends upon the extent to which the microinjected molecules and endogenous molecules behave similarly. Three observations suggest that the iodinated HMG1 and HMG2 molecules, employed as probes, are equivalent to their endogenous counterparts. First, HMG1 and HMG2 concentrate in the nuclei of injected cells, and they are present on mitotic chromosomes.

FIGURE 4

Distribution of [125I]HMG2 in binucleate cells formed by fusion of injected and uninjected cells. 20 h after injection of [125I]HMG2 into HeLa cells, the injected cells were collected and mixed with a twofold excess of uninjected cells containing fluorescent beads. The resulting mixture was plated onto glass cover slips and grown overnight. The cells were then fused with Sendai virus and fixed with 3.7% glutaraldehyde at various times. After autoradiographic processing, binucleate cells were examined, and the number of grains overlying the more heavily labeled nucleus was divided by the number of grains over the less heavily labeled nucleus to produce the ratio plotted on the abscissa. Only cells which contained fluorescent beads and at least 25 grains over nuclei were scored.
The labeled proteins, therefore, display at least some of the binding characteristics of the native proteins. Second, injected HMG1 and HMG2 display high stability in HeLa, 3T3, and BF cells. Because altered proteins are often rapidly degraded (7, 24, 28), this observation provides further evidence that the labeled HMGs behave like native molecules. Third, microinjected proteins and the failure of other proteins to accumulate in the nuclei is not obviously related to the isoelectric points or sizes of the protein. Our present data for HMG1 and HMG2 display high stability in HeLa, 3T3, and BF cells. Because altered proteins are often rapidly degraded (7, 24, 28), this observation provides further evidence that the labeled HMGs behave like native molecules.

Fractionation of 3T3 Cells Injected with \(^{125}\text{I}\)-HMGI and \(^{131}\text{I}\)-HMG2

| Fraction          | \(\text{[^{125}\text{I}]HMGI} \) | \(\text{[^{131}\text{I}]HMG2} \) | \(\text{HMG2/HMGI} \)
|-------------------|-----------------|-----------------|------------------|
| Whole cell        | 10,400 100      | 14,375 100      |                  |
| RSB extracts      | 3,336 32        | 3,659 28        |                  |
| Triton extract    | 1,138 13        | 2,048 14        |                  |
| 0.35 M NaCl extract | 392 7          | 746 5          |                  |
| Nuclear pellet    | 5,347 51        | 7,331 51        |                  |

3T3 cells were microinjected with \(^{125}\text{I}\)-HMGI and \(^{131}\text{I}\)-HMG2 and trypsinized the next day. The recovered cells were divided into three portions; one portion was immediately fractionated; the other two portions were replated into flasks. The low density flasks contained 1.8 x 10^8 cells and 10% FCS. The high density flasks contained 1.8 x 10^9 cells plus 5% serum and \(10\mu\text{Ci/ml}[^3\text{H}]\text{thymidine.}\) After incubation for 2 h, the cover slips were rinsed, and the cells were fixed with 3% glutaraldehyde. The fraction of cells in S-phase was determined by radioautography. At each sampling the remaining cells in the flasks were rinsed with phosphate-buffered saline, dissolved in 100 mM NaOH, and the intracellular radioactivity was measured.

The presence of HMG1 and HMG2 in cytoplasmic fractions is not surprising, since a number of nuclear proteins are known to leak from nuclei during aqueous cell fractionation. For example, DNA polymerase \(\alpha\), which is present in cytoplasmic fractions upon aqueous cell fractionation, is located within nuclei isolated by nonaqueous techniques (13, for review reference 22). Because our autoradiographic studies show \(^{128}\text{I}\)-HMGI and \(^{131}\text{I}\)-HMG2 to be intranuclear (Fig. 1), their recovery in cytoplasmic fractions clearly represents leakage during fractionation.

The affinity with which HMGI is bound to chromatin varies from one cell type to another, and this appears to be due to differences in the chromatin rather than to differences in the

---

**Table III**

| Relationship Between Cellular Growth Rate and Degradation Rates of HMG1 and HMG2 |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Hours after injection               | Growth condition            | Cells in S-phase \%          | Radioactivity                |
|-------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| 24                                  | High density                | 10                          | \[^{125}\text{I}]\text{HMGI}    | 1,311                        | 1,238                        | 0.94                         |
| 72                                  | Low density                 | 65                          | \[^{131}\text{I}]\text{HMG2}    | 1,299                        | 1,206                        | 0.93                         |
| 120                                 | High density                | 9                           | \[^{125}\text{I}]\text{HMGI}    | 1,219                        | 1,151                        | 0.94                         |
|                                     | Low density                 | 57                          | \[^{131}\text{I}]\text{HMG2}    | 1,479                        | 1,372                        | 0.93                         |

3T3 cells were trypsinized and collected 20 h after coinjection with \(^{125}\text{I}\)-HMGI and \(^{131}\text{I}\)-HMG. The injected cells were suspended in F12 medium with 0.1% FCS and were distributed into two sets of 75-cm flasks, each of which contained a glass cover slip. One set (high cell density) contained 0.9 x 10^6 injected cells plus 2.4 x 10^6 unjected 3T3 cells per flask, and a FCS concentration of 0.1%. The other set of flasks (low cell density) contained 0.9 x 10^6 injected cells per flask and 5% serum. At 24, 72, and 120 h after plating, the cover slips were taken from the flasks and placed in 60-mm petri dishes containing regular growth medium and F12 medium containing 5% serum and 10 μCi/ml[^3H]thymidine. After incubation for 2 h, the cover slips were rinsed, and the cells were fixed with 3% glutaraldehyde. The fraction of cells in S-phase was determined by radioautography. At each sampling the remaining cells in the flasks were rinsed with phosphate-buffered saline, dissolved in 100 mM NaOH, and the intracellular radioactivity was measured.

**Table IV**

| Fractionation of 3T3 Cells Injected with \(^{125}\text{I}\)-HMGI and \(^{131}\text{I}\)-HMG2 |
|------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| 20 h after injection                     | Low density                 | 120 h after injection       | High density                |
| Fraction                                | \[^{125}\text{I}]\text{HMGI} | \[^{131}\text{I}]\text{HMG2} | \[^{125}\text{I}]\text{HMGI} | \[^{131}\text{I}]\text{HMG2} |
| Whole cell                              | 10,400 100                  | 14,375 100                  | 24,600 100                  | 22,600 100                  |
| RSB extracts                            | 3,336 32                    | 3,659 28                    | 4,453 18                    | 3,712 16                    |
| Triton extract                          | 1,138 13                    | 2,048 14                    | 3,353 14                    | 3,858 17                    |
| 0.35 M NaCl extract                     | 392 7                       | 746 5                      | 1,884 7                     | 2,546 11                    |
| Nuclear pellet                          | 5,347 51                    | 7,331 51                   | 13,876 58                   | 12,361 55                   |

3T3 cells were microinjected with \(^{125}\text{I}\)-HMGI and \(^{131}\text{I}\)-HMG2 and trypsinized the next day. The recovered cells were divided into three portions; one portion was immediately fractionated; the other two portions were replated into flasks. The low density flasks contained 1.8 x 10^8 cells and 10% FCS. The high density flasks contained 1.8 x 10^9 cells plus 5% serum and \(10\mu\text{Ci/ml}[^3\text{H}]\text{thymidine.}\) After incubation for 2 h, the cover slips were rinsed, and the cells were fixed with 3% glutaraldehyde. The fraction of cells in S-phase was determined by radioautography. At each sampling the remaining cells in the flasks were rinsed with phosphate-buffered saline, dissolved in 100 mM NaOH, and the intracellular radioactivity was measured.
HMG1 molecules. When HeLa cells were fractionated, endogenous HMG1 and HMG2 were found mainly in the cytoplasm, whereas most of the HMG1 of calf thymus remained associated with the nuclear pellet during fractionation. That this is due to tissue, rather than species specificity, is suggested by the observation that \(^{125}\text{I}-\)labeled HMG1 from a single species (calf), when added to homogenates of the two tissues, fractionated in each case like the endogenous HMG1.

Although we have observed apparent tight-binding forms of HMG1 and HMG2, these are probably of little physiological significance. The fact that the tight-binding fraction of injected \(^{125}\text{I}-\)HMG1 was not within isolated BF nuclei indicates either that it is artificially produced during fractionation or that HMG1 molecules are bound to some nuclear component which is released during isolation. The possibility that \(^{125}\text{I}-\)HMG1 was degraded and that \(^{125}\text{I}-\)iodotyrosine was incorporated into some insoluble protein is not tenable. First, it is known that iodotyrosine is not incorporated into proteins (44); and second, both acid-urea and SDS-acrylamide electrophoresis gave no evidence for labeled proteins other than HMG1.

Grain counts obtained from cells microinjected with \(^{125}\text{I}-\)HMG2 suggest that 5–10% of the HMG2 molecules are localized in the cytoplasm. However, as discussed above, some cytoplasmic grains may arise from HMG2 molecules which are present in the nucleus. The HMG2 found in cytoplasmic fractions by Seyedin and Kistler could, likewise, result from redistribution of the protein during cell fractionation. However, our observation that the introduction of an unlabeled nucleus into a previously microinjected cell is followed by an equilibration of the labeled HMG2 molecules between the two nuclei provides evidence for the existence of a cytoplasmic pool of HMG2 and further demonstrates that the HMG2 molecules in this pool are in equilibrium with those bound to the chromatin. We previously found that HMG1 migrates between nuclei (41). The rapidity with which microinjected HMGI and HMG2 enter the nucleus and the rapidity with which these proteins exit from the nucleus upon disruption of the cell are also consistent with a model in which there is an equilibrium between nuclear and cytoplasmic pools of these proteins. Thus, in contrast to the core histones which appear to be permanently associated with DNA (35, 43), microinjected HMGI1 and HMG2 (and presumably endogenous HMGI1 and HMG2 molecules) maintain a state of dynamic equilibrium between the cytoplasm and the chromatin. Comings and Harris have proposed that many nonhistone chromosomal proteins behave in this manner (10).

In our study we failed to detect any differences in the intracellular behavior of injected HMGI1 and HMG2. This high degree of similarity between the two proteins, expected on the basis of protein structure, was somewhat surprising, given the results of Seyedin and Kistler (46). Their studies suggested that HMGI1 and HMG2 would differ in the properties examined here. Proteins whose intracellular concentration fluctuates greatly in response to environmental stimuli, usually turn over rapidly (14, 15), but the half-life of HMG2 was not significantly different from that of HMGI1 in either growing or nongrowing 3T3 cells. Moreover, if HMG2 plays a role in cell replication, it presumably does so by interacting with chromatin in a specific fashion. Yet, the apparent binding of HMG2 to chromatin was equivalent to that of HMGI1, which has not been implicated in replication. Injected HMGI1 and HMG2 displayed identical distributions upon fractionation of HeLa cells, and both molecules equilibrated between nuclei with similar kinetics. While these measurements are not extremely sensitive, they clearly suggest that HMGI1 and HMG2 bind to chromatin at similar sites with association constants of the same magnitude. All of our results, then, are consistent with HMGI1 and HMG2 performing closely related functions within cells. While we did not observe any growth-related differences in the degradation of HMG2 in cultured cells, it is possible that this regulatory mechanism only operates in vivo or that differential synthesis of HMGI1 and HMG2 is responsible for growth-related changes in their concentration. Clearly, further work will be required to determine whether the hypothesis that HMG2 plays a role in cell replication is generally valid.

We wish to thank Le Tran, who performed most of the grain counts, and Maurine Vaughan, for typing the final manuscript.

This work was supported by United States Public Health Service Grants GM 13864, GM 24617 and GM 27159.

Received for publication 10 June 1981, and in revised form 13 July 1981.

REFERENCES

1. Baker, C., I. Isenberg, G. H. Goodwin, and E. W. Johns. 1976. Physical studies of the nonhistone chromosomal proteins HMGI1 and HMG2. Biochemistry. 15:1645–1649.
2. Bonner, W. M., and R. A. Langer. 1974. A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur. J. Biochem. 46:83–88.
3. Buskin, M., R. B. Hopkins, and I. Isenberg. 1978. Immunological relationship of a high mobility group chromosomal protein from calf thymus. J. Biol. Chem. 253:1294–1299.
4. Bonser, W. M. 1975. Protein migration into nuclei. I. Frog oocyte nuclei in vivo accumulate microinjected histones, allow entry to small proteins, and exclude large proteins. J. Cell Biol. 64:421–430.
5. Bonser, W. M. 1975. Protein migration into nuclei. II. Frog oocyte nuclei accumulate a class of microinjected oocyte nuclear proteins and exclude a class of microinjected oocyte chromatin proteins. J. Cell Biol. 64:431–437.
6. Buskin, M., and N. K. Nehart. 1979. Antibodies against chromosomal HMGI proteins stain the cytoplasm of mammalian cells. Cell 1:181–189.
7. Capocci, M. R., N. E. Capocci, D. Altman, D. Hughes, and G. M. Wahl. 1974. Selective degradation of abnormal proteins in mammalian tissue culture cells. Proc. Natl. Acad. Sci. U. S. A. 71:4732–4736.
8. Cary, P. C., C. Crane-Robinson, E. Bradford, K. Jakavaherian, G. Goodwin, and E. O. 1976. Conformational studies of two non-histone chromosomal proteins and their interactions with DNA. Eur. J. Biochem. 62:583–590.
9. Cary, P. D., K. V. Shooter, G. H. Goodwin, E. W. Johns, J. Y. Olayemi, P. G. Hartman, and E. M. Bradford. 1979. Does high-mobility-group non-histone protein HMGI1 interact specifically with histone H1 subfractions? Biochem. J. 183:657–662.
10. Comings, D. E., and D. C. Harris. 1976. Nuclear proteins. II. Similarity of nonhistone proteins in nuclear sap and chromatin and essential absence of chromatin proteins from liver and muscle nuclei. J. Cell Biol. 70:440–452.
11. DeRobertis, E. M., R. F. Longhorn, and J. B. Gurdon. 1978. Intracellular migration of nuclear proteins in Xenopus oocytes. Nature (Lond.). 272:254–256.
12. Eagle, H., K. A. Paxt, R. Pfeifenback, and W. J. Okusa. 1959. Protein turnover in mammalian cell cultures. J. Biol. Chem. 234:592–597.
13. Foster, D. N., and T. Gursey, Jr. 1976. Nuclear location of mammalian DNA polymerase activities. J. Biol. Chem. 251:7173–7179.
14. Goldberg, A., and H. F. Diac. 1974. Intracellular protein degradation in mammalian and bacteria cells. Annu. Rev. Biochem. 43:855–870.
15. Goldberg, A., and A. Y. Shih. 1976. Intracellular protein degradation in mammalian and bacteria cells. Annu. Rev. Biochem. 45(Pt. 2):727–724.
16. Goodwin, G. H., and E. W. Johns. 1978. Are the high mobility group proteins associated with “active” chromatin? Biochim. Biophys. Acta. 919:279–284.
17. Goodwin, G. H., R. H. Nicolais, and E. W. Johns. 1975. An improved large-scale fractionation of high mobility group non-histone chromatin proteins. Biochim. Biophys. Acta. 405:280–291.
18. Goodwin, G. H., L. Woodhead, and E. W. Johns. 1977. The presence of high mobility group non-histone chromatin protein in isolated nucleosomes. FEBS Lett. 73:85–88.
19. Goodwin, G. H., J. M. Walker, and E. W. Johns. 1978. The high mobility group (HMG) nonhistone chromosomal proteins. The Cell Nucleus. H. Busch, editor. Academic Press, Inc., New York. 6:182–217.
20. Gordon, J. S., J. Bruno, and J. J. Lucas. 1981. Heterogeneous binding of high mobility group chromosomal proteins to nuclei. J. Cell Biol. 83:373–379.
21. Gordon, J. B. 1970. Nuclear transplantation and the control of gene activity in animal development. Proc. Royal Soc. Lond. B. Biol. Sci. 176:303–314.
22. Gursey, T., Jr., and D. N. Foster. 1976. Nonaqueous isografting of nuclei from cultured cells. Methods Cell Biol. 16:45–68.
23. Hancock, R. 1969. Conservation of histories in chromatin during growth and mitosis in Tetrahymena. J. Cell Biol. 40:221–235.
24. Hunt, W. M. 1975. Protein redistribution of high mobility group chromosomal proteins. Biochemistry. 15:1645–1649.
25. Hendzel, K. B. 1975. Degradation of abnormal proteins in HeLa cells. J. Cell. Physiol. 87:289–296.
26. Jakavaherian, K. 1977. Conformation of HMG nonhistone proteins and their interactions with DNA and histones. In Organization and Expression of Eukaryotic Genome. E. M. Bradbury and K. Jakavaherian, editors. Academic Press, Inc., London. 51–65.
27. Johs, E. W., G. H. Goodwin, J. M. Walker, and C. Sanders. 1976. Chromosomal proteins related to histones. In The Structure and Function of Chromatin. Ciba Foundation
28. Knowlton, S. E., J. M. Guzzi, R. W. Hansou, and F. J. Ballard. 1975. Increased degradation rates of protein synthesized in Hepatoma cells in the presence of amino acid analogues. *Biochim. J.* 146:595-600.

29. Kuehle, L. 1979. Synthesis of high mobility group proteins in regenerating rat liver. *J. Biol. Chem.* 254:7276-7281.

30. Kuehle, L., T. Lyness, D. C. Watson, and G. H. Dixon. 1979. Binding of HMG-1 to trout testis chromatin. *Biochim. Biophys. Acta.* 90:351-397.

31. Kuehle, L., T. Lyness, G. H. Dixon, B. Levy-Wilson. 1980. Distribution of high mobility group proteins along domains of trout testis chromatin differing in their susceptibility to micrococcal nuclease. *J. Biol. Chem.* 255:1090-1095.

32. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* 227:680-685.

33. Levy, W. R., W. Connor, and B. H. Dixon. 1979. A subset of trout testis nucleosomes enriched in transcribed DNA sequences contains high mobility group proteins as major structural components. *J. Biol. Chem.* 254:609-620.

34. Levy-Wilson, B., L. Kuehle, and G. H. Dixon. 1980. The release of high mobility group protein H16 and Protamine gene sequences upon selective DNAse I degradation of trout testis chromatin. *Nucl. Acid Res.* 8:2857-2870.

35. Manz, T., T. Thacher, and M. Rechsteiner. 1980. Arginine-rich histones do not exchange between human and mouse chromosomes in hybrid cells. *Cell.* 19:993-1003.

36. Miyachi, Y., J. L. Vaitukaitis, E. Nieschlag, and M. B. Lipsett. 1972. Enzymatic radioiodination of gonadotropins. *J. Clin. Endocrinol. Metab.* 34:23-28.

37. Panyim, S., and R. Chalkley. 1969. High resolution acrylamide gel electrophoresis of high mobility group proteins. *Biochim. Biophys. Acta.* 130:337-346.

38. Penman, S. 1966. RNA metabolism in the HeLa cell nucleus. *J. Mol. Biol.* 17:117-130.

39. Peters, E. H. B., Levy-Wilson, and G. H. Dixon. 1979. Evidence for the location of high mobility group protein T in the internucleosomal linker regions of trout testis chromatin. *J. Biol. Chem.* 254:3358-3361.

40. Rechsteiner, M. 1978. Red cell-mediated microinjection. *Nat. Cancer Inst. Monogr.* 48:57-64.

41. Rechsteiner, M., and L. Kuehle. 1979. Microinjection of the recombinant chromosomal protein HMG-1 into bovine fibroblasts and HeLa cells. *Cell.* 16:901-908.

42. Rechsteiner, M., K. Lund, D. Hilliard, and B. Olivera. 1974. Autoradiographic studies of pyridine nucleotide metabolism in human cells. *J. Cell. Physiol.* 83:289-400.

43. Riley, J. F. 1963. Comparison of the incorporation of tyrosine and its iodinated analogs into the proteins of Ehrlich ascites tumor cells and rat-liver slices. *Biochem. Biophys. Acta.* 78:759-762.

44. Schlegel, R., and M. Rechsteiner. 1975. Microinjection of thymidine kinase and bovine serum albumin into mammalian cells by fusion with red blood cells. *Cell.* 5:371-379.

45. Seyedin, S. M., and W. S. Kistler. 1979. Levels of chromosomal protein high mobility group 2 parallel the proliferative activity of testis, skeletal muscle and other organs. *J. Biol. Chem.* 254:11264-11271.

46. Shoote, R., and H. Weintraub. 1974. Interactions of purified non-histone chromosomal protein with DNA and histone. *Eur. J. Biochem.* 47:263-270.

47. Smith, S. J., D. Robertson, M. S. C. Birbeck, G. H. Goodwin, and E. W. Johns. 1978. Immunohistochimical studies of high mobility group non-histone chromatin proteins HMG1 and HMG2. *Biochemistry.* 17:4242-4247.

48. Walker, J. M., R. B. Hastings, and E. W. Johns. 1977. The primary structure of a non-histone chromosomal protein. *Eur. J. Biochem.* 78:661-668.

49. Walker, J. M., R. B. Hastings, and E. W. Johns. 1978. A novel continuous sequence of 41 aspartic and glutamic residues in a non-histone chromosomal protein. *Nature (Wash. D. C.)* 271:281-282.

50. Vidali, G., L. C. Botfa, and V. G. Allfrey. 1977. Selective release of chromosomal proteins during limited DNAse I digestion of avian erythrocyte chromatin. *Cell.* 12:409-415.

51. Walker, J. M., R. B. Hastings, and E. W. Johns. 1977. The similarity between the primary structures of two non-histone chromosomal proteins. *Eur. J. Biochem.* 62:461-469.

52. Walker, J. M., R. B. Hastings, and E. W. Johns. 1977. A comparison of the amino-terminal sequences of two calf-thymus chromatin non-histone proteins. *Int. J. Pept. Protein Res.* 9:220-223.

53. Walker, J. M., E. W. Johns. 1979. The isolation, characterization and partial sequence of a peptide rich in glutamic acid and aspartic acid (HGA-2 peptide) from calf thymus non-histone chromosomal protein HMG-2. *Biochem. J.* 179:255-254.

54. Walker, J. M., G. H. Goodwin, and E. W. Johns. 1970. The primary structure of the nucleosome-associated chromosomal protein HMG14. *Eur. J. Biochem.* 100:394-398.

55. Walker, J. M., and E. W. Johns. 1976. Chromosomal subunits in active genes have an altered conformation. *Science (Wash. D. C.)* 193:848-856.

56. Weintraub, M., and E. W. Johns. 1980. Interaction of HMG14 and 17 with the chromatin protein HMG-1. *Proc. Natl. Acad. Sci. U. S. A.* 76:782-784.

57. Weisbrod, S., and H. Weintraub. 1979. Isolation of a subclass of nuclear proteins responsible for conferring a DNase I-sensitive structure on globin chromatin. *Proc. Natl. Acad. Sci. U. S. A.* 76:430-434.

58. Walker, J. M., G. H. Goodwin, and E. W. Johns. 1978. A novel continuous sequence of 41 aspartic and glutamic residues in a non-histone chromosomal protein. *Nature (Wash. D. C.)* 271:281-282.

59. Whalen, M., and M. Groudine. 1976. Chromosomal subunits in active genes have an altered conformation. *Science (Wash. D. C.)* 193:848-856.

60. Walker, J. M., and B. S. Kistler. 1979. Levels of chromosomal protein high mobility group 2 parallel the proliferative activity of testis, skeletal muscle and other organs. *J. Biol. Chem.* 254:11264-11271.

61. Shoote, R., and H. Weintraub. 1974. Interactions of purified non-histone chromosomal protein with DNA and histone. *Eur. J. Biochem.* 47:263-270.

62. Smith, S. J., D. Robertson, M. S. C. Birbeck, G. H. Goodwin, and E. W. Johns. 1978. Immunohistochimical studies of high mobility group non-histone chromatin proteins HMG1 and HMG2. *Biochemistry.* 17:4242-4247.